FC
XBI icon

Fairscale Capital’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Fairscale Capital’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$60.9K Hold
385
– – 0.04% 190
2026
Q1 		$49.2K Buy
385
+138
+56% +$17.2K 0.03% 198
2025
Q4 		$30.1K Hold
247
– – 0.02% 229
2025
Q3 		$24.7K Hold
247
– – 0.02% 256
2025
Q2 		$21.2K Buy
247
+236
+2,145% +$18.8K 0.02% 264
2025
Q1 		$892 Hold
11
– – ﹤0.01% 327
2024
Q4 		$991 Hold
11
– – ﹤0.01% 330
2024
Q3 		$1.09K Hold
11
– – ﹤0.01% 323
2024
Q2 		$1.12K Buy
+11
New +$986 ﹤0.01% 329

Other funds holding XBI

BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Fairscale Capital's XBI Position: Q2 2026 in Review

Fairscale Capital held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q2 2026 at 385 shares worth $60.9K. The position accounts for 0.04% of the portfolio, ranked #190.

Fairscale Capital first reported a position in XBI in Q2 2024 and has held it in 9 quarters since. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

  • Fairscale Capital held 385 shares of State Street SPDR S&P Biotech ETF worth $60.9K as of Q2 2026.
  • Fairscale Capital left its State Street SPDR S&P Biotech ETF share count unchanged in Q2 2026.
  • State Street SPDR S&P Biotech ETF made up 0.04% of Fairscale Capital's portfolio in Q2 2026, its #190 holding.
  • Fairscale Capital first reported a position in State Street SPDR S&P Biotech ETF in Q2 2024 and has held it in 9 quarters since.
  • 933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Fairscale Capital's 13F filing for Q2 2026, filed 7 Aug 2026.